Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management / Matucci-Cerinic M.; Bruni C.; Allanore Y.; Clementi M.; Dagna L.; Damjanov N.S.; De Paulis A.; Denton C.P.; Distler O.; Fox D.; Furst D.E.; Khanna D.; Krieg T.; Kuwana M.; Lee E.B.; Li M.; Pillai S.; Wang Y.; Zeng X.; Taliani G.. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - ELETTRONICO. - 79:(2020), pp. S724-S726. [10.1136/annrheumdis-2020-217407]

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

Matucci-Cerinic M.;Bruni C.
Membro del Collaboration Group
;
Li M.
Membro del Collaboration Group
;
2020

Abstract

Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
2020
79
S724
S726
Goal 3: Good health and well-being for people
Matucci-Cerinic M.; Bruni C.; Allanore Y.; Clementi M.; Dagna L.; Damjanov N.S.; De Paulis A.; Denton C.P.; Distler O.; Fox D.; Furst D.E.; Khanna D.; Krieg T.; Kuwana M.; Lee E.B.; Li M.; Pillai S.; Wang Y.; Zeng X.; Taliani G.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1204560
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 49
social impact